Clinical trials: Sirolimus, completed
Metastatic Colorectal Cancer
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.
- Trial name
- NCT01154335
- Testing
- OSI-906, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- SCRI Development Innovations, LLC
Coronary Artery Disease
First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease
The DESSOLVE I clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent SES.
- Trial name
- DESSOLVE-I (NCT01247428)
- Testing
- MiStent SES
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 30 people
- Sponsor
- Micell Technologies
Coronary Artery Disease, Type 2 Diabetes Mellitus
Comparison Between Pioglitazone and SES With type2 DM
Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents.
- Trial name
- NCT00482183
- Testing
- Pioglitazone
- Volunteers
- 38 people
- Sponsor
- Showa University
Unspecified Adult Solid Tumor, Protocol Specific
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects, best way to give, and best dose of CCI-779 and EKB-569 in treating patients with advanced solid tumors.
- Trial name
- NCT00098501
- Testing
- pelitinib, temsirolimus
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in…
- Trial name
- NCT01014351
- Testing
- Paclitaxel, Carboplatin, Everolimus
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
End-Stage Renal Disease
Pediatric Kidney Transplant Without Calcineurin Inhibitors
The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease.
- Trial name
- NCT00023231
- Testing
- Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
Recipients from living donors kidneys HLA-identical were lower risk for acute rejection, graft loss or death. There is no clear definition of what is ideal immunosuppressive regimen for this population.
- Trial name
- NCT01653041
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 47 people
- Sponsor
- Hospital do Rim e Hipertensão
Ischemic Heart Disease, Restenosis
Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial
The use of DES have not diminished the need of improved treatment strategies , especially the treatment of bifurcation lesions still leave much to be clarified.
- Trial name
- SINGLEKISS (NCT00798954)
- Testing
- Sirolimus-eluting coronary stent (Cypher), Paclitaxel-eluting stent (TAXUS)
- Where
- 17 sites in Japan
- Volunteers
- 800 people
- Sponsor
- Vulnerable Plaque Society
Advanced Cancer
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable…
- Trial name
- NCT00610493
- Testing
- Bevacizumab, Temsirolimus, Additional Blood Drawn
- Where
- United States
- Volunteers
- 193 people
- Sponsor
- M.D. Anderson Cancer Center
Uveitis
Daclizumab and Sirolimus to Treat Uveitis
This study will examine whether the combination of the drugs daclizumab and sirolimus can effectively treat adults with uveitis, an eye inflammation.
- Trial name
- NCT00078689
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Renal Transplantation
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
Efficacy and safety of 2 groups of treatment: everolimus in association with cyclosporine microemulsion and steroids versus everolimus in association with Enteric-coated Mycophenolate Sodium (EC-MPS) and steroids.
- Trial name
- NCT00425308
- Testing
- Everolimus + Cyclosporine, Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS), Steroids
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Graft Versus Host Disease, Leukemia
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00577278
- Testing
- rituximab, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma
Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
Temsirolimus is a drug that is being studied to possibly treat kidney cancer. It works by starving the cancer of nutrients, by cutting off the blood supply, which is hoping to shrink the cancer.
- Trial name
- NCT01404104
- Testing
- Temsirolimus (pre surgery)
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Sickle Cell-thalassemia Disease, Thalassemia
Haploidentical Hematopoietic Stem Cell Transplantation
The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia.
- Trial name
- NCT02165007
- Testing
- peripheral blood stem cell graft that are CD34+ selected
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Catherine Bollard
Melanoma (Skin)
CCI-779 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic…
- Trial name
- NCT00022464
- Testing
- temsirolimus
- Where
- 21 sites in United States, Canada
- Sponsor
- City of Hope Medical Center
Kidney Transplantation, Kidney Transplantation Recipients
Effect of Probiotics on Immunosuppressant Therapy in Kidney Transplant Recipients
People who receive a donor kidney must take drugs to prevent their bodies from attacking the new organ. These drugs are called immunosuppressants. Probiotics are beneficial microbes that support gut health.
- Trial name
- PITON (NCT07884084)
- Testing
- Probiotic formulation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
This clinical trial studies how well early stem cell transplantation works in treating patients with high-grade myeloid neoplasms that has come back after a period of improvement or does not respond to treatment.
- Conditions
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome
- Trial name
- NCT02756572
- Testing
- Cladribine, Cyclosporine, Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Coronary Artery Disease
DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery Disease
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting SeQuent Please S stent system (DEBlue) in the treatment of stenoses in native coronary arteries with nominal stent diameters between ≥ 2.5 mm and…
- Trial name
- PEPCADIII (NCT00473772)
- Testing
- DEBlue stent vs. Cypher stent
- Where
- 16 sites in Belgium, Czechia and 6 more
- Volunteers
- 643 people
- Sponsor
- University Hospital, Saarland
Cardiovascular Abnormalities
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the lymphatic-vascular organisations.
- Trial name
- vasca-LM (NCT01811667)
- Testing
- Sirolimus
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.